One-year efficacy and safety of avatrombopag for chronic immune thrombocytopenia in Japanese adults

• EHA •
• 13 June, 2026 •
• •

Avatrombopag in TPO RA–naive adults in acute, persistent, and chronic phases of ITP: results from the REAL AVA 3.0 retrospective study

Sandhya Panch, Abiola Oladapo, Faizan Sattar, Michael Vredenburg , Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Debbie Jiang

Available materials

• EHA •
• 12 June, 2026 •
• •

Impact of protocol mandated dose holds on platelet response durability in pediatric ITP treated with avatrombopag: AVA 301 post hoc analysis

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Amanda Grimes, Michele Lambert, Jessica Zhang, Brian D. Jamieson, Chelsea Bernheisel, Michael Vredenburg , Faizan Sattar

Available materials

• ASH •
• 8 December, 2025 •
• •

Patient-reported outcomes of avatrombopag for chronic immune thrombocytopenia: Interim analysis of the Phase 4 adopt study

María Eva Mingot Castellano, María Teresa Álvarez Román, María Luisa Lozano, Wolfgang Miesbach, Hafiz Qureshi, Vickie McDonald, Jessica Zhang, Viridiana Cano Garcia, Nina Skuban